Drug General Information
Drug ID	D0D1YY
Former ID	DIB006282
Drug Name	IGN-2098
Drug Type	Small molecular drug
Indication	Duodenal ulcers [ICD10:K25-K27]		Discontinued in Phase 2	[544900]
Company	Ikeda Mohando Co Ltd
Structure		Download 2D MOL 3D MOL
Formula	C22H32Cl2N4O2
Canonical SMILES	n1c(=O)c(c([nH]c1NC/C=C\COc1cc(CN2CCCCC2)ccc1)C)C.Cl.Cl
CAS Number	CAS 126868-88-0
PubChem Compound ID	6443221
Target and Pathway
Target(s)	Histamine H2 receptor	Target Info	Antagonist	[526772]
KEGG Pathway	Calcium signaling pathway
	Neuroactive ligand-receptor interaction
	Gastric acid secretion
PANTHER Pathway	Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
	Histamine H2 receptor mediated signaling pathway
PathWhiz Pathway	Intracellular Signalling Through Histamine H2 Receptor and Histamine
	Gastric Acid Production
Reactome	Histamine receptors
	G alpha (s) signalling events
WikiPathways	Monoamine GPCRs
	GPCRs, Class A Rhodopsin-like
	Secretion of Hydrochloric Acid in Parietal Cells
	GPCR ligand binding
	GPCR downstream signaling
References
Ref 544900	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001447)
Ref 526772	Effects of IGN-2098, a new histamine H2-receptor antagonist, on gastric secretion and gastric and duodenal lesions induced in rats. Comparison with roxatidine. Nihon Yakurigaku Zasshi. 1992 Mar;99(3):167-80.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.